Industries > Pharma > Head and Neck Cancer Drugs Market Report 2019-2029
Head and Neck Cancer Drugs Market Report 2019-2029
Forecasts by Treatment (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy), by Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), by Distribution Channel (Hospitals, Online Providers, Drug Stores & Retail Pharmacies) Plus Analysis of Leading Companies
List of head and neck cancer drugs providers identified in this report are Bristol-Myers Squibb, Merck, Sanofi, Eli Lilly, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Limited.
Head and Neck Cancer Drugs Market Report 2019-2029, By Treatment
– Surgery
– Radiation Therapy
– Chemotherapy
– Immunotherapy
Head and Neck Cancer Drugs Market Report 2019-2029, By Therapeutic Class
– PD Inhibitors
– EGFR Inhibitors
– Microtubule Inhibitors
Head and Neck Cancer Drugs Market Report 2019-2029, By Distribution Channel
– Hospitals
– Online Providers
– Drug stores & retail pharmacies
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Global Head and Neck Cancer Drugs Market Overview
1.2. Why You Should Read This Report
1.3. How This Report Delivers
1.4. Key Questions Answered by This Analytical Report Includes:
1.5. Who is This Report For?
1.6. Methodology
1.7. Frequently Asked Questions (FAQ)
1.8. Associated Visiongain Reports
1.9. About Visiongain
2. Introduction to the Head and Neck Cancer Drugs Market
2.1. What is Head and Neck Cancer Drugs?
2.2. Treatment Of Head and Neck Cancer Drugs Industry
2.2.1. Surgery
2.2.2. Radiation Therapy
2.2.3. Chemotherapy
2.2.4. Immunotherapy
2.3. Therapeutic Class of Head and Neck Cancer Drugs
2.3.1. PD Inhibitors
2.3.2. EGFR Inhibitors
2.3.3. Microtubule Inhibitors
2.4. Distribution Channels of Head and Neck Cancer Drugs
2.4.1. Hospitals
2.4.2. Online Providers
2.4.3. Drug stores & retail pharmacies
2.5. Factors Impacting Head and Neck Cancer Drugs Market
2.6. Healthcare Industry By Geography
2.7. Market Dynamics among Leading Brands
2.8. Patent Expiry Schedule
2.9. Strategic Framework
2.10. Pricing and Reimbursement
2.11. Emerging Markets
2.12. Biosimilar Evolution
2.13. Incidence and Prevalence rate by Geography
2.14. Profile of Disruptive Drugs
2.14.1. Opdivo
2.14.2. Keytruda
2.14.3. Imfinzi
2.14.4. Bavencio
2.14.5. Yervoy
2.14.6. Tremelimumab
2.14.7. Buparlisib
2.14.8. Epacadostat
3. Head and Neck Cancer Drugs Market Outlook
3.1. Trends in Head and Neck Cancer Drugs Industry
3.2. Market Drivers
3.3. Market Restraints
3.4. PESTEL Analysis
3.5. Porter’s Five Forces Model
3.6. Competitive Environment Analysis, 2019
3.7. SWOT Analysis
4. Head and Neck Cancer Drugs Market By Treatment 2019 – 2029
4.1. Head and Neck Cancer Drugs Market Outlook By Treatment 2019 – 2029
4.2. Surgery Treatment Revenue Forecast 2019 – 2029
4.3. Radiation Therapy Treatment Revenue Forecast 2019 – 2029
4.4. Chemotherapy Treatment Revenue Forecast 2019 – 2029
4.5. Immunotherapy Treatment Revenue Forecast 2019 – 2029
5. Head and Neck Cancer Drugs Market By Therapeutic Class 2019 – 2029
5.1. Head and Neck Cancer Drugs Market Outlook By Therapeutic Class 2019 – 2029
5.2. PD Inhibitors Revenue Forecast 2019 – 2029
5.3. EGFR Inhibitors Revenue Forecast 2019 – 2029
5.4. Microtubule Inhibitors Revenue Forecast 2019 – 2029
6. Head and Neck Cancer Drugs Market By Distribution Channel 2019 – 2029
6.1. Head and Neck Cancer Drugs Market Outlook By Distribution Channel 2019 – 2029
6.2. Head and Neck Cancer Drugs Revenue Forecast For Hospitals 2019 – 2029
6.3. Head and Neck Cancer Drugs Revenue Forecast For Online Providers 2019 – 2029
6.4. Head and Neck Cancer Drugs Revenue Forecast For Drug stores & retail pharmacies 2019 – 2029
7. Head and Neck Cancer Drugs Market By Region 2019 – 2029
7.1. Head and Neck Cancer Drugs Market Outlook By Region 2019 – 2029
7.2. North America Revenue Forecast 2019 – 2029
7.2.1. U.S. Revenue Forecast 2019 – 2029
7.2.2. Canada Revenue Forecast 2019 – 2029
7.2.3. Mexico Revenue Forecast 2019 – 2029
7.3. Europe Revenue Forecast 2019 – 2029
7.3.1. Germany Revenue Forecast 2019 – 2029
7.3.2. UK Revenue Forecast 2019 – 2029
7.3.3. Russia Revenue Forecast 2019 – 2029
7.4. Asia Pacific Revenue Forecast 2019 – 2029
7.4.1. China Revenue Forecast 2019 – 2029
7.4.2. Japan Revenue Forecast 2019 – 2029
7.4.3. India Revenue Forecast 2019 – 2029
7.5. Central & South America Revenue Forecast 2019 – 2029
7.5.1. Brazil Revenue Forecast 2019 – 2029
7.5.2. Argentina Revenue Forecast 2019 – 2029
7.5.3. Colombia Revenue Forecast 2019 – 2029
7.6. Middle East & Africa Revenue Forecast 2019 – 2029
7.6.1. Saudi Arabia Revenue Forecast 2019 – 2029
7.6.2. UAE Revenue Forecast 2019 – 2029
8. The Leading Head and Neck Cancer Drugs Companies 2019 – 2029
8.1. Major Head and Neck Cancer Drugs Companies
8.2. Bristol-Myers Squibb
8.3. Merck
8.4. Sanofi
8.5. Eli Lilly
8.6. AstraZeneca Plc.
8.7. F. Hoffmann-La Roche Ltd.
8.8. Fresenius Medical Care AG & Co. KGaA
8.9. Pfizer Inc.
8.10. Sun Pharmaceutical Industries Ltd.
8.11. Teva Pharmaceutical Industries Limited
8.12. List of Other Companies
9. Conclusions & Recommendations
9.1. Key Findings in the Head and Neck Cancer Drugs Market
9.2. Recommendations for the Head and Neck Cancer Drugs Market
10. Glossary
List of Tables
10.1. Global Head and Neck Cancer Drugs Market, 2019 & 2029 (USD billion)
10.2. Global Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.3. Global Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.4. North America Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.5. North America Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.6. North America Head and Neck Cancer Drugs Market, by Country, 2019-2029 (USD billion)
10.7. U.S. Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.8. U.S. Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.9. Canada Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.10. Canada Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.11. Europe Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.12. Europe Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.13. Europe Head and Neck Cancer Drugs Market, by Country, 2019-2029 (USD billion)
10.14. Germany Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.15. Germany Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.16. UK Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.17. UK Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.18. Russia Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.19. Russia Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.20. Asia Pacific Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.21. Asia Pacific Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.22. Asia Pacific Head and Neck Cancer Drugs Market, by Country, 2019-2029 (USD billion)
10.23. Japan Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.24. Japan Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.25. China Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.26. China Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.27. India Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.28. India Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.29. Rest of the World Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.30. Rest of the World Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.31. Rest of the World Head and Neck Cancer Drugs Market, by Country, 2019-2029 (USD billion)
10.32. Brazil Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.33. Brazil Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
10.34. Saudi Arabia Head and Neck Cancer Drugs Market, by Treatment, 2019-2029 (USD billion)
10.35. Saudi Arabia Head and Neck Cancer Drugs Market, by Therapeutic Class, 2019-2029 (USD billion)
List of Figures
10.36. Research Methodology
10.37. Market Size Estimation Methodology
10.38. Forecasting Methodology
10.39. Global Head and Neck Cancer Drugs Market, DRO Analysis
10.40. Global Head and Neck Cancer Drugs Market, Company Share Analysis
10.41. Global Head and Neck Cancer Drugs Market, Interview Demographics
10.42. PESTEL Analysis
10.43. Global Head and Neck Cancer Drugs Market Segmentation
10.44. Global Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Treatment, 2019 & 2029
10.45. Global Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Therapeutic Class, 2019-2029
10.46. Global Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Geography, 2019-2029
10.47. North America Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Treatment, 2019 & 2029
10.48. North America Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Therapeutic Class, 2019-2029
10.49. North America Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Country, 2019-2029
10.50. Europe Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Treatment, 2019 & 2029
10.51. Europe Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Therapeutic Class, 2019-2029
10.52. Europe Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Country, 2019-2029
10.53. Asia Pacific Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Treatment, 2019 & 2029
10.54. Asia Pacific Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Therapeutic Class, 2019-2029
10.55. Asia Pacific Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Country, 2019-2029
10.56. Rest of the World Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Treatment, 2019 & 2029
10.57. Rest of the World Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Therapeutic Class, 2019-2029
10.58. Rest of the World Head and Neck Cancer Drugs Market Share and Y-o-Y Growth, by Country, 2019-2029
Bristol-Myers Squibb
Merck
Sanofi
Eli Lilly
AstraZeneca Plc.
F. Hoffmann-La Roche Ltd.
Fresenius Medical Care AG & Co. KGaA
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited
Download sample pages
Complete the form below to download your free sample pages for Head and Neck Cancer Drugs Market Report 2019-2029
Download sample pages
Complete the form below to download your free sample pages for Head and Neck Cancer Drugs Market Report 2019-2029
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Latest Pharma news
Visiongain Publishes Biologics Market Report 2024-2034
The biologics market is estimated at US$447 billion in 2023 and is projected to grow at a CAGR of 8.5% during the forecast period 2024-2034.
20 November 2023
Visiongain Publishes mRNA Vaccines Market Report 2023-2033
The global mRNA Vaccines market is estimated at US$11,773.3 million in 2023 and is projected to grow at a CAGR of 10.5% during the forecast period 2023-2033.
08 November 2023
Visiongain Publishes Stem Cell Technologies and Applications Market Report 2023-2033
The global Stem Cell Technologies and Applications market is estimated at US$10,059.6 million in 2023 and is projected to grow at a CAGR of 8.7% during the forecast period 2023-2033.
06 November 2023
Visiongain Publishes Neurology Clinical Trials Market Report 2023-2033
The global Neurology Clinical Trials market is valued at US$9,609.2 million in 2023 and is projected to grow at a CAGR of 5.4% during the forecast period 2023-2033.
01 November 2023